According to the AP, Neuronetics will hear word from the FDA on January 26, 2007 regarding whether its transcranial magnetic stimulation (TMS) treatment will receive FDA approval for treating depression.
Psychiatric medications, science, marketing, psychiatry in general, and occasionally clinical psychology. Questioning the role of key opinion leaders and the use of "science" to promote commercial ends rather than the needs of people with mental health concerns.
No comments:
Post a Comment